文献速递帕金森病与运动障碍

羟丁酸钠治疗孤立性局灶性喉部肌张力障碍的疗效与安全性:一项IIb期双盲安慰剂对照交叉随机临床试验

Efficacy and Safety of Sodium Oxybate in Isolated Focal Laryngeal Dystonia: A Phase IIb Double-Blind Placebo-Controlled Cross-Over Randomized Clinical Trial.
PubMed 文献 · Ann Neurol · 2024-11-20

本研究为IIb期双盲安慰剂对照两周期交叉随机临床试验,纳入106例孤立性喉部肌张力障碍患者,评估羟丁酸钠对比安慰剂的疗效与安全性。主要结局为给药后40分钟症状严重度较基线的变化。结果显示,酒精反应阳性患者症状改善具有统计学显著性,而酒精反应阴性患者无显著改善;常见不良事件为轻度头晕、恶心和日间嗜睡。

要点

  • 酒精反应阳性患者接受羟丁酸钠后症状较安慰剂有统计学显著改善,酒精反应阴性患者无显著改善。
  • 酒精反应阳性患者症状改善≥16%的比值比为2.09,平均获益40.81%。
  • 药效在给药后300分钟减弱,未出现反弹;认知功能、自杀倾向和生命体征无变化。

核心结论

  • 羟丁酸钠在酒精反应阳性喉部肌张力障碍患者中显示出有临床意义的症状改善,耐受性可接受。
  • 羟丁酸钠提供了首个针对喉部肌张力障碍病理生理机制的口服治疗选择。

研究设计与样本

  • IIb期随机双盲安慰剂对照两周期交叉临床试验,于2018年1月至2021年12月在麻省眼耳医院进行,期间因COVID-19疫情暂停。
  • 纳入106例孤立性喉部肌张力障碍患者,其中53例先接受羟丁酸钠1.5g,53例先接受匹配安慰剂。
  • 患者、研究者和结局评估者对研究程序设盲。

主要发现

  • 与基线相比,酒精反应阳性患者接受羟丁酸钠后喉部肌张力障碍症状较安慰剂有统计学显著改善(98.75% CI = 0.6-26.9;p = 0.008);酒精反应阴性患者无统计学显著改善(98.75% CI = -6.2至18.7;p = 0.42)。
  • 酒精反应阳性患者中,症状改善≥16%时药物最低疗效具有统计学显著性(OR = 2.09;98.75% CI = 0.75-5.80;p = 0.036),平均获益40.81%(98.75% CI = 34.7-48.6)。
  • 药效在给药后300分钟减弱,未出现反弹。
  • 认知功能、自杀倾向或生命体征未见变化。
  • 常见不良事件包括轻度头晕、恶心和日间嗜睡。

临床怎么用

  • 作者认为,羟丁酸钠为喉部肌张力障碍提供了首个病理生理相关的口服治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the efficacy and safety of sodium oxybate versus placebo in a phase IIb randomized double-blind placebo-controlled 2-period cross-over clinical trial in patients with isolated laryngeal dystonia (LD). METHODS: The study was conducted from January 2018 to December 2021, pausing during the COVID-19 pandemic, at Massachusetts Eye and Ear in 106 patients with alcohol-responsive (EtOH+) and alcohol-non-responsive (EtOH-) LD (53 to receive 1.5g of sodium oxybate first, 53 to receive matching placebo first). The primary outcome was a change from baseline in LD symptom severity 40 minutes after drug intake. Safety was based on vital signs, cognitive function, suicidality, daytime sleepiness, and adverse events. Patients, investigators, and outcome assessors were masked to study procedures. RESULTS: Compared to baseline, EtOH+ but not EtOH- patients had a statistically significant improvement in LD symptoms following sodium oxybate versus placebo (EtOH+: 98.75% confidence interval [CI] = 0.6-26.9; p = 0.008; EtOH-: 98.75% CI = -6.2 to 18.7; p = 0.42). Statistically significant minimum drug efficacy in EtOH+ patients was found at ≥16% symptom improvement (OR = 2.09; 98.75% CI = 0.75-5.80; p = 0.036), with an average of 40.81% benefits (98.75% CI = 34.7-48.6). Drug efficacy waned by 300 minutes after intake without a rebound. No changes were found in cognitive function, suicidality, or vital signs. Common adverse events included mild dizziness, nausea, and daytime sleepiness. INTERPRETATION: Sodium oxybate showed clinically meaningful improvement of symptoms in EtOH+ LD patients, with acceptable tolerability. Sodium oxybate offers the first pathophysiologically relevant oral treatment for laryngeal dystonia. ANN NEUROL 2025;97:329-343.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Simonyan K, O'Flynn LC, Hamzehei Sichani A, et al. Efficacy and Safety of Sodium Oxybate in Isolated Focal Laryngeal Dystonia: A Phase IIb Double-Blind Placebo-Controlled Cross-Over Randomized Clinical Trial. Ann Neurol. 2024. PMID: 39565101. doi:10.1002/ana.27121

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。